BR112018001376A2 - tratamento para vitiligo - Google Patents

tratamento para vitiligo

Info

Publication number
BR112018001376A2
BR112018001376A2 BR112018001376A BR112018001376A BR112018001376A2 BR 112018001376 A2 BR112018001376 A2 BR 112018001376A2 BR 112018001376 A BR112018001376 A BR 112018001376A BR 112018001376 A BR112018001376 A BR 112018001376A BR 112018001376 A2 BR112018001376 A2 BR 112018001376A2
Authority
BR
Brazil
Prior art keywords
alkyl
hydrogen
alkoxy
halo
subject
Prior art date
Application number
BR112018001376A
Other languages
English (en)
Inventor
Rubenstein David
Catherine Dickson Marion
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112018001376A2 publication Critical patent/BR112018001376A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

um método de tratamento de vitiligo, incluindo profilaxia, em um sujeito que dele necessite, compreendendo a administração ao referido sujeito de uma quantidade farmaceuticamente eficaz de um composto de fórmula (i): (i) em que: x é cr1 ou n; y é ch, c ou n; r1 é hidrogênio, c1-6 alcóxi ou c1-6 alquila; r2 é hidrogênio, c1-6 alcóxi, halo, -c(o)c1-6 alquila, cn, halo-c1-6 alquila ou -c(o)nr4r5; r3 é hidrogênio ou c1-6 alcóxi; r4 é hidrogênio ou c1-6 alquila: r5 é hidrogênio ou c1-6 alquila; e m e n são números inteiros cada um independentemente selecionado a partir de 1 e 2, ou um seu sal farmaceuticamente aceitável.
BR112018001376A 2015-07-24 2016-07-21 tratamento para vitiligo BR112018001376A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196349P 2015-07-24 2015-07-24
PCT/IB2016/054355 WO2017017571A1 (en) 2015-07-24 2016-07-21 Treatment for vitiligo

Publications (1)

Publication Number Publication Date
BR112018001376A2 true BR112018001376A2 (pt) 2018-09-11

Family

ID=56557861

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001376A BR112018001376A2 (pt) 2015-07-24 2016-07-21 tratamento para vitiligo

Country Status (11)

Country Link
US (1) US20180207172A1 (pt)
EP (1) EP3324950B1 (pt)
JP (1) JP2018521089A (pt)
KR (1) KR20180031719A (pt)
CN (1) CN108024972A (pt)
AU (1) AU2016300199B2 (pt)
BR (1) BR112018001376A2 (pt)
CA (1) CA2993288A1 (pt)
ES (1) ES2781332T3 (pt)
RU (1) RU2018106663A (pt)
WO (1) WO2017017571A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
EP2376481B1 (en) 2009-01-13 2013-08-07 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
GB201104153D0 (en) * 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2895172B1 (en) * 2012-09-12 2019-02-06 Rigel Pharmaceuticals, Inc. Treatment for vitiligo

Also Published As

Publication number Publication date
US20180207172A1 (en) 2018-07-26
EP3324950A1 (en) 2018-05-30
EP3324950B1 (en) 2020-01-15
AU2016300199A1 (en) 2018-02-08
CN108024972A (zh) 2018-05-11
KR20180031719A (ko) 2018-03-28
CA2993288A1 (en) 2017-02-02
WO2017017571A1 (en) 2017-02-02
ES2781332T3 (es) 2020-09-01
JP2018521089A (ja) 2018-08-02
RU2018106663A (ru) 2019-08-26
AU2016300199B2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MY182590A (en) Benzylamine derivatives
PH12016501204A1 (en) Syk inhibitors
NZ715747A (en) Syk inhibitors
NZ726366A (en) Syk inhibitors
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015028879A2 (pt) derivados heterocíclicos
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
ECSP16082790A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
AR094277A1 (es) Derivados de fumarato sustituidos con deuterio
PE20160670A1 (es) PIRROLO[1,2-f][1,2,4]TRIAZINAS UTILES PARA TRATAR INFECCIONES POR EL VIRUS SINCITIAL RESPIRATORIO
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX343740B (es) Derivados de bencilamina como inhibidores de calicreina plasmatica.
BR112014001801A2 (pt) indazóis
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
BR112014015402A8 (pt) composição sólida de cuidado pessoal, produto de cuidado pessoal e método de tratar cabelo e/ou pele
BR112014026760A2 (pt) inibidores de éter cabeça de ponte cíclico dgat1
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
BR112013028486A2 (pt) método para promover crescimento de planta
BR112013028598A2 (pt) método para promover o crescimento de plantas
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
UA112769C2 (uk) Аміноінданові сполуки і їх застосування при лікуванні болю
DK201300268A (da) Ny Behandling
PH12015501492A1 (en) Benzylamine derivatives

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired